Jules A A C Heuberger
Overview
Explore the profile of Jules A A C Heuberger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
288
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gorbenko A, Heuberger J, Juachon M, Klaassen E, Tagen M, Lawler J, et al.
Clin Pharmacol Ther
. 2025 Feb;
PMID: 39898464
Emergency department visits due to cannabinoid-induced toxicity, including acute cannabinoid intoxication (ACI) have increased worldwide as more states have liberalized cannabis policy. ACI symptoms include anxiety, panic attacks, tachycardia, and...
2.
Ruijs T, de Cuba C, Heuberger J, Hutchison J, Bold J, Gronnebaek T, et al.
Clin Pharmacol Ther
. 2024 Dec;
117(3):768-778.
PMID: 39651850
NMD670 is a first-in-class inhibitor of skeletal muscle-specific chloride channel ClC-1, developed to improve muscle weakness and fatigue in neuromuscular diseases. Preclinical studies show that ClC-1 inhibition enhances muscle excitability,...
3.
de Cuba C, de Goede A, Klaassen E, Otto M, Doll R, Kim J, et al.
Clin Pharmacol Ther
. 2024 Dec;
117(3):787-797.
PMID: 39641417
Current anti-epileptic drugs lack efficacy, cause many side effects and one third of all patients are treatment-resistant. Drugs targeting the sphingosine-1-phosphate receptor show potential anti-convulsant effects in animal models and...
4.
Gorbenko A, Heuberger J, Klumpers L, de Kam M, Strugala P, de Visser S, et al.
Clin Pharmacol Ther
. 2024 Jul;
116(5):1289-1303.
PMID: 39054656
Cannabidiol (CBD), the main non-intoxicating compound in cannabis, has been hypothesized to reduce the adverse effects of Δ-tetrahydrocannabinol (THC), the main psychoactive and analgesic component of cannabis. This clinical trial...
5.
Skov M, Ruijs T, Gronnebaek T, Skals M, Riisager A, Winther J, et al.
Sci Transl Med
. 2024 Mar;
16(739):eadk9109.
PMID: 38507469
Myasthenia gravis (MG) is a neuromuscular disease that results in compromised transmission of electrical signals at the neuromuscular junction (NMJ) from motor neurons to skeletal muscle fibers. As a result,...
6.
Dijkstra F, Zuiker R, Heuberger J, Kanhai K, de Kam M, Duvauchelle T, et al.
Br J Clin Pharmacol
. 2023 Sep;
90(1):321-335.
PMID: 37724688
Aims: To characterise the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of oxathridine, a first-in-class histamine-3 receptor partialagonist, in healthy male volunteers. Methods: A randomised, double-blind,...
7.
Vissers M, Troyer M, Thijssen E, Pereira D, Heuberger J, Groeneveld G, et al.
Clin Transl Sci
. 2023 May;
16(8):1408-1420.
PMID: 37177855
Increased leucine-rich repeat kinase 2 (LRRK2) kinase activity is an established risk factor for Parkinson's disease (PD), and several LRRK2 kinase inhibitors are in clinical development as potential novel disease-modifying...
8.
Jennings D, Huntwork-Rodriguez S, Vissers M, Daryani V, Diaz D, Goo M, et al.
Mov Disord
. 2023 Feb;
38(3):386-398.
PMID: 36807624
Background: Leucine-rich repeat kinase 2 (LRRK2) inhibition is a promising therapeutic approach for the treatment of Parkinson's disease (PD). Objective: The aim of this study was to evaluate the safety,...
9.
Ruijs T, Koopmans I, de Kam M, Tannemaat M, Groeneveld G, Heuberger J
Clin Transl Sci
. 2022 Oct;
15(12):2971-2981.
PMID: 36281627
Measuring muscle velocity recovery cycles (MVRCs) is a method to obtain information on muscle cell excitability, independent of neuromuscular transmission. The goal was to validate MVRC as a pharmacodynamic (PD)...
10.
Sleutjes B, Stikvoort Garcia D, Kovalchuk M, Heuberger J, Groeneveld G, Franssen H, et al.
Pharmacol Res Perspect
. 2022 Jul;
10(4):e00983.
PMID: 35881020
Altered motor neuron excitability in patients with amyotrophic lateral sclerosis (ALS) has been suggested to be an early pathophysiological mechanism associated with motor neuron death. Compounds that affect membrane excitability...